CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia

Heart. 2011 Jul;97(14):1151-7. doi: 10.1136/hrt.2010.220699. Epub 2011 May 12.

Abstract

Objective: To determine the calcium score and coronary plaque burden in asymptomatic statin-treated patients with heterozygous familial hypercholesterolaemia (FH) compared with a control group of patients with low probability of coronary artery disease, having non-anginal chest pain, using CT.

Design, setting and patients: 101 asymptomatic patients with FH (mean age 53 ± 7 years; 62 men) and 126 patients with non-anginal chest pain (mean age 56 ± 7 years; 80 men) underwent CT calcium scoring and CT coronary angiography. All patients with FH were treated with statins during a period of 10 ± 8 years before CT. The coronary calcium score and plaque burden were determined and compared between the two patient groups.

Results: The median total calcium score was significantly higher in patients with FH (Agatston score = 87, IQR 5-367) than in patients with non-anginal chest pain (Agatston score = 7, IQR 0-125; p < 0.001). The overall coronary plaque burden was significantly higher in patients with FH (p < 0.01). Male patients with FH, whose low-density lipoprotein cholesterol levels were reduced by statins below 3.0 mmol/l, had significantly less coronary calcium (p < 0.01) and plaque burden (p = 0.02).

Conclusion: The coronary plaque burden is high in asymptomatic middle-aged patients with FH despite intense statin treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asymptomatic Diseases
  • Calcinosis / diagnostic imaging
  • Calcinosis / etiology
  • Case-Control Studies
  • Chi-Square Distribution
  • Coronary Angiography / methods*
  • Coronary Artery Disease / diagnostic imaging*
  • Coronary Artery Disease / genetics
  • Female
  • Genetic Predisposition to Disease
  • Heterozygote
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / genetics
  • Linear Models
  • Male
  • Middle Aged
  • Netherlands
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Severity of Illness Index
  • Tomography, X-Ray Computed*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors